Aura Biosciences, INC 8-K filings

Aura Biosciences announced Q2 2026 results, a strategic shift to ocular oncology, workforce reduction, and key leadership appointments, extending cash runway to 1H 2029.

Aura Biosciences successfully increased its authorized common stock and approved an amendment to its stock option plan at a recent stockholder meeting.

Aura Biosciences has appointed Dr. Jeremy Bender to its Board of Directors, effective July 7, 2026, to bolster its strategic and operational capabilities.

Aura Biosciences stockholders elected two Class II directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

Aura Biosciences has completed a public offering of common stock and pre-funded warrants, raising approximately $280.8 million in net proceeds.

Aura Biosciences announced an agreement to repurchase up to 6,922,870 shares of its common stock from Matrix Capital Management Master Fund, LP, funded by proceeds from an upcoming equity offering.

Aura Biosciences announced the appointment of Natalie Holles as CEO and President, succeeding founder Elisabet de los Pinos, as the company's Phase 3 CoMpass trial nears enrollment completion.

Aura Biosciences accelerated enrollment in its Phase 3 CoMpass trial, guided mid-2026 completion and 2H 2027 topline data, reported a wider FY25 net loss, and affirmed cash runway into Q1 2027.

Aura Biosciences provides updated timelines for its Phase 3 CoMpass trial in early choroidal melanoma, reports Q3 2025 financial results, and highlights positive immune profiling data for bel-sar in bladder cancer.

Aura Biosciences reported Q2 2025 financial results and significant progress in its ocular and urologic oncology clinical programs, bolstered by a $75 million equity financing.

Aura Biosciences, Inc. announced the successful election of two Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Aura Biosciences successfully closes a public offering, raising approximately $69.9 million to fund its clinical programs and extend its cash runway into the first half of 2027.

Aura Biosciences announces Q1 2025 financial results, highlighting progress in clinical trials for bel-sar in choroidal melanoma and bladder cancer, along with the appointment of a new Chief Financial and Business Officer.

Aura Biosciences expands its Board of Directors with the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, effective March 31, 2025.

Aura Biosciences reports positive Phase 1 trial data in bladder cancer, advances its clinical pipeline, and expects its cash position to support operations into the second half of 2026.

Aura Biosciences announced positive Phase 2 data for bel-sar in early-stage choroidal melanoma and promising Phase 1 results in non-muscle invasive bladder cancer, alongside its Q3 2024 financial results.

Aura Biosciences reported positive early results from its Phase 1 trial of bel-sar (AU-011) in non-muscle-invasive bladder cancer, showing multiple complete responses after a single low dose.

Aura Biosciences' Chief Financial Officer, Julie Feder, will depart on October 25, 2024, with Amy Elazzouzi appointed as interim CFO and principal accounting officer.

Aura Biosciences reported positive Phase 2 end-of-study results for bel-sar (AU-011) showing significant tumor control and vision preservation in patients with early-stage choroidal melanoma.

Aura Biosciences announced its second quarter 2024 financial results and highlighted progress in its clinical programs, including upcoming data presentations for bladder and ocular cancer treatments.

Aura Biosciences has amended its charter to limit officer liability, following approval at its 2024 Annual Meeting of Stockholders.

Aura Biosciences is presenting at the Jefferies Global Healthcare Conference, providing an update on their clinical programs and corporate strategy, including a focus on their lead candidate Bel-sar.

Aura Biosciences announced its first quarter 2024 financial results, highlighting continued progress in its clinical trials and a strong cash position.

Aura Biosciences announces the resignation of board member Raj Parekh, effective June 20, 2024, following the company's annual meeting.

Aura Biosciences announced its full year 2023 financial results, highlighted by the advancement of its Phase 3 trial for choroidal melanoma and expansion into bladder cancer, with a strong cash position extending into the second half of 2026.